Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034922.xml
Download PDF
Arthritis und Rheuma 2017; 37(06): 418-422
DOI: 10.1055/s-0038-1624233
DOI: 10.1055/s-0038-1624233
Kasuistik
Ofatumumab plus Fresh Frozen Plasma bei systemischem Lupus erythematodes mit ausgeprägter Hypokomplementämie
Ofatumumab plus Fresh Frozen Plasma at systemic lupus erythematosus with pronounced hypocomplementemiaFurther Information
Publication History
Publication Date:
10 January 2018 (online)
-
Literatur
- 1 Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015; 11 (06) 329-341.
- 2 Ambrose N, Morgan TA, Galloway J. et al. Differences in disease phenotype and severity in SLE across age groups. Lupus 2016; 25 (14) 1542-1550.
- 3 Petri M, Orbai A-M, Alarcón GS. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64 (08) 2677-2686.
- 4 bESID – European Society for Immunodeficiencies [Internet]. [cited 2017 Jun 4]. Available from: https://esid.org/Working-Parties/Registry/Diagnosis-criteria.
- 5 Anolik JH, Barnard J, Owen T. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56 (09) 3044-3056.
- 6 Anolik JH, Barnard J, Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50 (11) 3580-3590.
- 7 Vital EM, Dass S, Buch MH. et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011; 63 (10) 3038-3047.
- 8 Zhu L, Yin Z, Ju B. et al. Altered frequencies of memory B cells in new-onset systemic lupus erythematosus patients. Clin Rheumatol. 2017 Oct 25.
- 9 Furst DE. Serum immunoglobulins and risk of infection: how low can you go?. Semin Arthritis Rheum 2009; 39 (01) 18-29.
- 10 Nazir HF, Elshinawy M, AlRawas A. et al. Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia. J Pediatr Hematol Oncol 2017; 39 (03) 203-208.
- 11 Arad U, Tzadok S, Amir S. et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29 (08) 1643-1648.
- 12 Mahmoud I, Jellouli M, Boukhris I. et al. Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017 Jun 8.
- 13 Watson L, Beresford MW, Maynes C. et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015; 24 (01) 10-17.
- 14 El-Hallak M, Binstadt BA, Leichtner AM. et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 2007; 150 (04) 376-382.
- 15 Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus 2015; 24 (09) 966-972.
- 16 Hogan J, Godron A, Baudouin V. et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol Berl Ger. 2017 Aug 5.
- 17 Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol Berl Ger 2017; 32 (06) 1013-1021.
- 18 Ale’ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int 2014; 34 (04) 529-533.
- 19 Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther 2013; 15 (Suppl. 01) S3.
- 20 Lin TS. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmacogenomics Pers Med 2010; 03: 51-59.
- 21 Wierda WG, Kipps TJ, Mayer J. et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28 (10) 1749-1755.
- 22 Md Yusof MY, Shaw D, El-Sherbiny YM. et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis 2017; 76 (11) 1829-1836.
- 23 Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J 2016; 09 (04) 552-555.
- 24 Taylor PC, Quattrocchi E, Mallett S. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011; 70 (12) 2119-2125.
- 25 Wang C-S, Liverman RS, Garro R. et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol Berl Ger 2017; 32 (05) 835-841.
- 26 Vivarelli M, Colucci M, Bonanni A. et al. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol Berl Ger 2017; 32 (01) 181-184.
- 27 Middleton O, Cosimo E, Dobbin E. et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 2015; 29 (01) 107-114.
- 28 Klepfish A, Schattner A, Ghoti H, Rachmilewitz EA. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol 2007; 08 (04) 361-362.
- 29 Fassbinder T, Saunders U, Mickholz E. et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther 2015; 17: 92.
- 30 Speth F, Wellinghausen N, Haas J-P. [Medicinal prophylaxis during intensified immunosuppression in children and adolescents: part 2]. Z Rheumatol 2013; 72 (09) 896-909.
- 31 Wang N, Shen N, Vyse TJ. et al. Selective IgA deficiency in autoimmune diseases. Mol Med Camb Mass 2011; 17 (11–12): 1383-1396.
- 32 Kaplan B, Kopyltsova Y, Khokhar A. et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract 2014; 02 (05) 594-600.
- 33 Reddy V, Klein C, Isenberg DA et al.. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatol Oxf Engl 2017; 56 (07) 1227-1237.
- 34 Speth F, Hinze C, Haas J-P. SAT0503 A Prospective Single-Centre Study on Indicators of Infectious Risk After Rituximab Therapy in Children and Adolescents with Rheumatic Diseases. Ann Rheum Dis 2015; 74 (Suppl. 02) 842.
- 35 Makatsori M, Kiani-Alikhan S, Manson A. et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM Mon J Assoc Physicians 2014; 107 (10) 821-828.